重组人红细胞生成素纠正胃癌患者术前贫血的临床观察

目的:探讨重组人红细胞生成素(recombinant human erythropoietin,rhEPO)纠正胃癌患者术前贫血的临床疗效,以尽可能减少异体输血。方法:2002-01-01-2004-12-31期间114例经手术治疗的胃癌患者中术前出现贫血(Hb<110 g／L,Hct<0．3,下同)的46例(40．4％)患者,随机分为研究组和对照组各23例。研究组在手术前后分别给予rhEPO1×104U,皮下注射,隔日1次,共6次,同时口服琥珀酸亚铁;对照组除按常规输异体血外,未作其他处理。结果:对照组中有21例在围手术期作了输血治疗,平均输异体血1 150 mL;研究组12例输入异体血,平均输血600 mL。研究组无术后并发症;对照组有4例出现术后并发症。同时研究显示,研究组手术当日Hb<90 g／L和Hct<0．3的病例数比对照组显著减少。结论:应用rhEPO可以减少异体输血,并使患者较平稳地度过围手术期。

Clinical observation of recombinant human erythropoietin in treatment of preoperative anemia in patients with gastric cancer

Objective: To investigate the clinical efficacy of recombinant human erythropoietin (rhEPO) in treatment of preoperative anemia in patients with gastric cancer, so as to reduce allogeneic blood transfusion. Methods: From January 2002 to December 2004, 114 patients underwent operation of gastric cancer. Of them. 46 were diagnosed to have preoperative anemia (Hb<110 g/L. Hct<0. 3, accounted for 40. 4%). The 46 cases were randomly divided into study group and control group. Twenty-three cancer patients in the study group received rhEPO 1 X 10' U hypodermie/qod. for 6 times, and took ferrous citrate orally at the same time. And 23 patients (control group) only received allogeneic blood transfusion. Results:Twenty-one cases in control group received allogeneic blood transfusion in preoperative period, the average quantity was 1 150 mL, And in study group there were 12 patients received allogeneic blood transfusion and the average quantity transfused was 600 mL. Complications occurred in 4 cases of the control group, but not in the study group. In study group, the cases with Hb<90 g/L and Hct<0. 3 on the operation day were less than those in the control group. Conclusion: After treatment with rhEPO, the allogeneic blood transfusion can be reduced, and the safety during perioperative period can be improved.